Zev Wainberg, MD, University of California Los Angeles, Los Angeles, CA, discusses promising preliminary results from an ongoing Phase I trial evaluating TTX-030 (a first-in-class anti-CD39 antibody) in combination with budigalimab (an investigational anti-PD-1 antibody) and FOLFOX for the first-line treatment of patients with locally advanced/metastatic HER2-negative gastric or gastroesophageal junction cancer. The primary endpoint is safety and tolerability with secondary endpoints of overall response rate (ORR) assessed using Response Evaluation criteria in Solid Tumors (RECIST/iRECIST) and progression free survival (PFS). TTX-030 is currently being studied in phase I/Ib clinical trials as a monotherapy and in combination with anti-PD-1 immunotherapy and standard chemotherapy in adults with advanced cancer (NCT03884556 and NCT04306900). This interview took place at the American Association for Cancer Research Annual Meeting 2022 in New Orleans, LA.
